Nuzyra Now Available in IV, Oral Forms for CABP, ABSSSI

Paratek also announced the availability of 3 FDA-approved antimicrobial susceptibility tests.

Paratek announced the launch of Nuzyra (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). It is the first once-daily antibiotic approved to treat CABP and ABSSSI that is available in both an intravenous (IV) and oral formulation.